admin – Page 33 – Get News Story

AV Access Launches 4KEX70W-H2: A 4K USB-C/HDMI Wall Plate Extender Engineered for Modern Classroom AV Systems

“”The 4KEX70W-H2 wall plate extender was designed to simplify classroom technology for educators while ensuring every student can clearly see and engage with instructional content.” — Bill Liao, CTO of AV Access”

4KEX70W-H2 extender is AV Access’s new 4K USB-C/HDMI Wall Plate Extender designed for multimedia classrooms. Dual HDMI and USB-C inputs, 21:9 and 32:9 ultrawide display support, 100W PD laptop charging, and stable 4K@60Hz transmission up to 70m/230ft over a Cat 6/6a cable — everything a modern classroom AV system needs, built into one clean wall plate.

AV Access, a leading provider of Pro AV and AV over IP solutions, today announces the launch of the 4KEX70W-H2, a 4K USB-C/HDMI wall plate extender designed for modern classrooms and meeting rooms. Supporting both HDMI and USB-C sources, the 4KEX70W-H2 installs directly into a wall or podium and delivers 4K@60Hz video up to 70m/230ft over existing Cat cabling — a reliable, professional-grade classroom AV equipment solution for schools and AV integrators.

Ultrawide and 4K Visuals That Reach Every Seat

“The 4KEX70W-H2 wall plate extender supports 21:9 and 32:9 ultrawide displays, so students get a full-width view of every presentation and video without black bars,” said Bill Liao, CTO at AV Access. “With stable 4K@60Hz transmission up to 70m/230ft, every student receives the same sharp, clear image whether seated in the front row or at the back of a large lecture hall.”

Both HDMI and USB-C inputs support full 4K@60Hz output, while 100W Power Delivery on the USB-C port maintains consistent laptop performance throughout the lesson, eliminating the need for separate charging adapters at the podium.

Plug In and Teach — Simple for Teachers, Integrators, and IT

Teachers can connect any laptop via HDMI or USB-C, with automatic input switching ensuring a seamless transition between sources. Installers benefit from a single Cat cable run and one power adapter powering the entire classroom AV system. For IT teams, bi-directional RS-232 and one-way IR deliver centralized control of projectors, displays, and switchers across the campus.

“With the 4KEX70W-H2 HDMI extender, schools can deliver a more engaging learning experience,” Bill concluded. “By simplifying content sharing and ensuring clear presentation visibility throughout the room, it helps educators spend less time managing technology and more time connecting with students.”

About AV Access

AV Access is a leading manufacturer and innovator of advanced Pro AV and AV over IP solutions. Its product portfolio includes HDMI/KVM extenders, splitters, switchers, KVM switches & docking stations, AV over IP, and wireless conferencing solutions— engineered for professionals across gaming, corporate, education, healthcare, and beyond. Learn more at www.avaccess.com.

Media Contact
Company Name: ACTIONS GLOBAL US INC
Contact Person: Nada Xi
Email: Send Email
Country: United States
Website: https://www.avaccess.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AV Access Launches 4KEX70W-H2: A 4K USB-C/HDMI Wall Plate Extender Engineered for Modern Classroom AV Systems

Washington Moves from Drone Customer to Drone Investor

For two decades, the federal government bought drones the way it bought trucks and radios. It wrote requirements, ran competitions, and purchased finished systems once they cleared testing. That model is bending. The next phase of America’s drone expansion has less to do with what the Pentagon buys than with what it is now willing to own.

A May 27 Wall Street Journal report describes the Trump administration in talks to fund a group of domestic drone manufacturers directly, through arrangements that could combine debt, conditional loans, and in some cases equity stakes that would give the federal government a slice of ownership. The talks run through the Office of Strategic Capital, a Pentagon lending arm the department says holds roughly $210 billion in authority. The objective is not to acquire aircraft. It is to expand production capacity and bring unit costs down.

The logic is arithmetic. The Pentagon’s Drone Dominance program intends to field roughly 300,000 low-cost attack drones by the end of 2027 under a $1.1 billion effort, targeting a price near $5,000 per unit. U.S. plants can currently build perhaps 100,000 drones a year. Ukraine built around four million last year. Closing that gap demands factories, qualified supply chains, and balance sheets that can scale, not simply better prototypes. Washington now appears willing to underwrite the build-out rather than wait for the market to deliver it.

That shift reorders the question program officers and investors ask. The advantage no longer belongs solely to the company with the strongest airframe. It increasingly belongs to the company built to absorb production capital, document a domestic supply chain, and operate under public-company discipline. Several established names show what that profile looks like at scale.

AIRO Group Holdings, Inc. (NASDAQ: AIRO) has organized itself explicitly around domestic capacity. In December the company completed the first RQ-35 ISR drones produced to full operational standard at its Phoenix, Arizona facility, a milestone it framed as central to a Made-in-America expansion strategy. AIRO reported a drone backlog of roughly $150 million entering 2026, most of it expected to convert within twelve months, and recently unveiled a full-scale hybrid-electric VTOL aircraft built for defense and dual-use logistics missions.

Teledyne Technologies Incorporated (NYSE: TDY) anchors the enabling-technology layer that any scaled drone fleet depends on. Its Teledyne FLIR Defense unit has delivered more than 35,000 Black Hornet nano-drones to military and security forces across more than 45 countries and in February secured a $17.5 million order from Switzerland’s defense procurement office. The company has also expanded an open payload-integration program and fielded Prism, an AI-driven counter-drone software platform, reflecting how sensors and software increasingly determine system value.

Draganfly Inc. (NASDAQ: DPRO) demonstrates how quickly public-safety drone makers are moving into defense. The company reported record first-quarter 2026 revenue of $2.31 million, up roughly 49% year over year, and in May the U.S. Army’s DEVCOM Army Research Laboratory selected the company and a partner to develop a modular counter-UAS platform. Draganfly also launched an NDAA-compliant optical payload line, extending a portfolio it has built across public safety and military markets over more than 25 years.

Against that backdrop, Dynamic Aerospace Systems (OTCQB: BRQL) is assembling itself around the precise attributes the new funding model rewards. The Ann Arbor manufacturer designs and builds unmanned systems for defense, public safety, and logistics, and it has spent the past year constructing the corporate machinery that production capital tends to require.

That machinery is visible in the company’s capital-markets posture. Dynamic Aerospace registered a $15 million equity line that went effective in December 2025, reserved the “DAS” ticker with the NYSE in anticipation of a future uplisting, and incurred legal, accounting, and S-1 related costs to strengthen its public-company infrastructure. Management frames those steps as preparation for institutional visibility and future financing rather than near-term expense.

The company has paired that posture with domestic supply-chain alignment. Its supplier agreement with Unusual Machines (NYSE: UMAC), one of the companies the Journal identified as a funding candidate, routes NDAA-compliant components into its Fortis Class line, placing Dynamic Aerospace inside the same domestically sourced ecosystem federal dollars are now chasing.

Execution continues to run through demonstrations. Over an eight-month span the company conducted a live flight for U.S. Air Force Global Strike Command at Strother Field in Kansas, hosted a multi-agency expo with the Arizona Department of Public Safety, and welcomed a Japanese defense delegation tied to Mitsubishi Heavy Industries, Kawasaki Heavy Industries, and other industrial leaders. Each event placed its US-1 multicopter, G1 VTOL, and Mitigator tactical drone in front of evaluators rather than on a slide.

The company has also expanded its intellectual property position to ten recent filings covering autonomous logistics, mobile fulfillment, structural-battery propulsion arms, and tactical systems, the kind of differentiated, protectable technology that strengthens a financing case.

Dynamic Aerospace remains pre-revenue and carries the execution risk early-stage defense companies do, the same risk that, in this category, has historically paired with outsized upside. The funding shift the Journal describes changes the terms of that risk. When Washington starts buying ownership in the industrial base rather than only its output, the companies positioned to benefit are those already built to be financed, supplied, and scaled. Dynamic Aerospace is building toward that test as the next chapter of America’s drone expansion takes shape.

Disclaimer: This is a paid editorial communication intended for informational purposes only. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. Please see WallStreetPR.com/Disclaimer for complete terms and conditions.

Media Contact
Company Name: WallstreetPR
Contact Person: Steve S
Email: Send Email
Phone: 214-506-0507
Address:1750 North Collins Blvd Suite 101-V
City: Richardson
State: https://wallstreetpr.com/
Country: United States
Website: https://wallstreetpr.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Washington Moves from Drone Customer to Drone Investor

Bulimia Nervosa Market Expected to Show Significant Growth Through 2036, estimates DelveInsight

The leading Bulimia Nervosa Companies are Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Allergan, Inc., Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Apotex Inc., and Teva Pharmaceutical Industries Ltd.

DelveInsight’s Bulimia Nervosa Market Insights, Epidemiology and Market Forecast 2036 provides the current and forecast market analysis, individual leading Bulimia Nervosa Companies market shares, challenges, Bulimia Nervosa Market Drivers, barriers, trends, and key market Bulimia Nervosa companies in the market.

To read more about the latest highlights related to the Bulimia Nervosa Market, get a snapshot of the key highlights entailed in the Market Report @https://www.delveinsight.com/sample-request/bulimia-nervosa-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Bulimia Nervosa Market Report

.In May 2025, CVS Health announced additional efforts to streamline its network and optimize store operations, including the closure of certain underperforming pharmacy locations while expanding pharmacy service offerings in areas with higher demand.
In October 2025, CVS Health published its annual pharmacy outlook report, emphasizing the continued leadership of retail pharmacies within the U.S. prescription market. The report also noted significant growth in the dispensing of medications for chronic conditions, including antidepressants and other mental health treatments.
In September 2025, the University of Oxford launched “Digital C BTe,” a structured digital cognitive behavioral therapy program designed for eating disorders such as bulimia nervosa. The initiative aims to improve access to treatment across the Asia-Pacific region and other underserved areas.
In September 2024, Lupin Limited secured U.S. FDA approval for Fluoxetine Tablets USP (10 mg, 20 mg, and 60 mg), broadening its portfolio of generic SSRIs used in the treatment of bulimia nervosa. Fluoxetine continues to be the only FDA-approved medication specifically indicated for bulimia nervosa in the United States.
In October 2025, Teva Pharmaceutical Industries Ltd received FDA approval to expand the use of UZEDY (long-acting risperidone injection) for the treatment of bipolar I disorder, further strengthening its central nervous system (CNS) portfolio and supporting psychiatric care services across the U.S. healthcare system.
Bulimia Nervosa is a serious psychiatric eating disorder characterized by recurrent episodes of binge eating followed by compensatory behaviors such as self-induced vomiting, excessive exercise, fasting, or misuse of laxatives. The disorder is strongly associated with distorted body image and emotional distress.
According to epidemiological data, the lifetime prevalence rates for bulimia nervosa ranged from 0.3 — 4.6% in females and from 0.1 — 1.3% in males, with one-year prevalence of 0.32% for females and 0.05% for males.
During the period from 1990 to 2021, the number of individuals affected by bulimia nervosa increased by 67%, rising from 7,416,420 cases to 12,367,024 cases, reflecting growing disease incidence globally.
The leading Bulimia Nervosa Companies such as Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Allergan, Inc., Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Apotex Inc., and Teva Pharmaceutical Industries Ltd.

To know more about why the 7MM regions are leading the market growth in the Bulimia Nervosa Market, get a snapshot @ Bulimia Nervosa Market Outlook-https://www.delveinsight.com/sample-request/bulimia-nervosa-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr

Bulimia Nervosa Market Dynamics

The Bulimia Nervosa market is experiencing gradual but meaningful growth driven by increasing awareness of eating disorders, rising diagnosis rates, expanding mental health infrastructure, and growing demand for integrated psychiatric care. The current treatment landscape is primarily multidisciplinary, combining psychotherapy, nutritional rehabilitation, behavioral interventions, and pharmacological management to achieve symptom control and relapse prevention. Cognitive behavioral therapy (CBT) remains the clinical gold standard and is widely recommended as the first-line intervention. Key factors such as growing mental health awareness, public awareness campaigns, educational initiatives reducing stigma associated with eating disorders, and the expansion of digital health and telemedicine services are creating a favorable environment for sustained market growth. Additionally, sociocultural pressures related to body image, dieting culture, and mental health challenges continue to increase the number of diagnosed cases and drive demand for therapeutic interventions from 2022 to 2036.

Bulimia Nervosa Market Segmentation Analysis

Bulimia Nervosa Market segmentation encompasses current treatment practices, marketed therapies, and off-label treatment options, with coverage across the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. The market is analyzed by epidemiology segments including total diagnosed prevalent cases, gender-specific diagnosed prevalent cases, age-specific diagnosed prevalent cases, and total treated cases of bulimia nervosa. Treatment approaches in the market are segmented by region and therapy type, reflecting variations in clinical practices across different geographies. The report provides comprehensive insight into the current treatment landscape, including cognitive behavioral therapy, interpersonal therapy, dialectical behavioral therapy, family-based therapy, nutritional counseling, and digital mental health programs used alongside pharmacological management.

Get a sneak peek at the Bulimia Nervosa Market Dynamics @ Bulimia Nervosa Market Dynamics Analysis-https://www.delveinsight.com/sample-request/bulimia-nervosa-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr

Bulimia Nervosa Companies

Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Allergan, Inc., Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd, and others.

Bulimia Nervosa Market Drivers

The demand for Bulimia Nervosa therapeutics is rising significantly, driven by multiple key factors. The rising prevalence of eating disorders, particularly among adolescents and young adults, is one of the major drivers of market growth. Growing mental health awareness through public awareness campaigns, mental health advocacy programs, and educational initiatives is reducing stigma associated with eating disorders, encouraging more patients to seek professional treatment. The expansion of digital health and telemedicine services, including digital therapeutics, telepsychiatry, mental health apps, and remote counseling services, is improving patient access to treatment, especially in underserved regions. Additionally, societal beauty standards and social media exposure emphasizing thinness contribute significantly to body dissatisfaction and unhealthy eating behaviors, increasing vulnerability to bulimia nervosa particularly among younger populations. These factors, combined with expanding mental health infrastructure and growing recognition of eating disorders as serious psychiatric conditions, are creating a favorable environment for sustained market growth during the forecast period.

Which MedTech key players in the Bulimia Nervosa Market are set to emerge as the trendsetter? Explore @ Bulimia Nervosa Companies-https://www.delveinsight.com/sample-request/bulimia-nervosa-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr

Scope of the Bulimia Nervosa Market Report

Coverage- 7MM
Study Period- 2022-2036
Forecast Period- 2026-2036
Bulimia Nervosa Companies- Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Allergan, Inc., Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd, and others.

Interested in knowing the Bulimia Nervosa Market by 2036? Click to get a snapshot of the Bulimia Nervosa Market Trends-https://www.delveinsight.com/sample-request/bulimia-nervosa-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr

Table of Contents

Key Insights
Report Introduction
Executive Summary
Key Events
Epidemiology and Market Forecast Methodology
Bulimia Nervosa Market Overview at a Glance
Disease Background and Overview of Bulimia Nervosa
Treatment
Epidemiology and Patient Population of Bulimia Nervosa
Patient Journey
Bulimia Nervosa: 7MM Analysis
Unmet Needs of Bulimia Nervosa
SWOT Analysis of Bulimia Nervosa
KOL Views of Bulimia Nervosa
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bulimia Nervosa Market Expected to Show Significant Growth Through 2036, estimates DelveInsight

Peanut Allergy Treatment Market Size in the 7MM was Valued at ~USD 533 Million in 2025 and is Expected to Reach ~USD 2,464 Million by 2034, Growing at a CAGR of 18.50%, Estimates DelveInsight

DelveInsight’s “Peanut Allergy Treatment Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Peanut Allergy, historical and forecasted epidemiology, as well as the Peanut Allergy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Takeaways from the Peanut Allergy Treatment Market Report

• The Peanut Allergy Treatment market in the 7MM was valued at approximately USD 533 million in 2025 and is projected to grow significantly during the forecast period (2025–2034).

• The Peanut Allergy Treatment Market is expected to grow at a CAGR of 18.50%, reaching approximately USD 2,464 million by 2034 across the 7MM.

• Peanut Allergy remains one of the most common and severe food allergies, affecting nearly 1–2% of the US population and demonstrating increasing prevalence globally, especially among pediatric populations.

• In 2024, the Peanut Allergy Diagnosed Prevalent Population in the 7MM was estimated at approximately 9.8 million cases, with the United States accounting for the highest number of diagnosed prevalent cases.

• Currently, PALFORZIA and XOLAIR are the only approved Peanut Allergy therapies, providing important treatment options for both pediatric and adult populations.

• In March 2025, the US FDA approved OMLYCLO (omalizumab-igec) as the first biosimilar designated interchangeable with XOLAIR for IgE-mediated food allergy treatment.

• The Peanut Allergy pipeline is advancing rapidly with innovative therapeutic approaches including BTK inhibitors, immunostimulants, immunomodulators, immunosuppressants, and epicutaneous immunotherapies.

• Key Peanut Allergy companies such as DBV Technologies, Novartis, Aravax, ALK-Abello, InnoUp Farma, Allergy Therapeutics, Intrommune Therapeutics, Roche, Regeneron Pharmaceuticals, and others are actively evaluating novel therapies.

Stay ahead in the Peanut Allergy Treatment Market with DelveInsight’s Strategic Report @ https://www.delveinsight.com/report-store/peanut-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Peanut Allergy Epidemiology Segmentation in the 7MM

• Total Diagnosed Prevalent Cases of Peanut Allergy

• Gender-specific Cases of Peanut Allergy

• Age-specific Cases of Peanut Allergy

• Severity-specific Cases of Peanut Allergy

• Country-wise Peanut Allergy Epidemiology

Key Factors Driving the Peanut Allergy Market

Rising Prevalence of Peanut Allergy

Peanut Allergy is among the most prevalent and severe food allergies worldwide, particularly affecting infants and children. Increasing incidence rates across major markets continue to create substantial demand for effective treatment and prevention strategies.

Current Market Landscape and Approved Therapies

The availability of approved therapies such as PALFORZIA and XOLAIR has significantly improved Peanut Allergy management. However, challenges related to continuous dosing requirements, treatment adherence, and patient accessibility continue to drive the development of next-generation therapies.

Clinical Trial Activity in Peanut Allergy

The Peanut Allergy pipeline is highly active, with clinical trials evaluating innovative therapies including Viaskin Peanut Patch, Remibrutinib, PVX108, SLIT-tablets, INP20, INT301, and others targeting multiple immune pathways.

Growing Research and Development Investments

Biopharmaceutical companies are investing heavily in the development of immunotherapy approaches including oral, sublingual, and epicutaneous immunotherapies aimed at improving desensitization and long-term tolerance.

Increasing Awareness and Diagnosis

Growing awareness regarding food allergy management, improved diagnostic tools, and updated clinical guidelines supporting early peanut introduction are contributing to earlier diagnosis and better disease management.

Download the report to understand which factors are driving @ Peanut Allergy epidemiology trends

Peanut Allergy Market and Pipeline Analysis

The evolving Peanut Allergy Treatment Market landscape features robust clinical development activities led by DBV Technologies (Viaskin [DBV712] Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (SLIT-Tablet), InnoUp Farma (INP20), Allergy Therapeutics (VLP Peanut), Intrommune Therapeutics (INT301), and Regeneron Pharmaceuticals (Linvoseltamab + Dupilumab).

Peanut Allergy Understanding

Peanut Allergy is a severe IgE-mediated immune disorder triggered by exposure to peanut proteins. The condition is associated with potentially life-threatening allergic reactions including anaphylaxis, significantly impacting patient quality of life and increasing healthcare burden.

Upon allergen exposure, Th2 immune responses stimulate IgE antibody production, which binds to mast cells and basophils. Subsequent allergen re-exposure activates these sensitized cells, leading to histamine release and inflammatory cascades responsible for allergic symptoms.

Peanut Allergy Diagnosis

Diagnosis of Peanut Allergy primarily relies on clinical history combined with confirmatory diagnostic testing. The gold standard remains the Double-Blind Placebo-Controlled Food Challenge (DBPCFC).

Additional diagnostic methods include:

• Skin Prick Tests (SPT)

• Serum IgE Testing

• Molecular Allergy Diagnostics

• Oral Food Challenge (OFC)

• Basophil Activation Testing

• Bead-based Epitope Assays (BBEA)

Advancements in molecular diagnostics and artificial intelligence-assisted allergy diagnostics are expected to improve diagnostic precision in the coming years.

Peanut Allergy Treatment Market

Current Peanut Allergy management strategies focus on allergen avoidance and emergency epinephrine administration for anaphylaxis management. However, immunotherapy approaches are transforming the treatment landscape.

Major immunotherapy strategies include:

• Oral Immunotherapy (OIT)

• Sublingual Immunotherapy (SLIT)

• Epicutaneous Immunotherapy (EPIT)

Desensitization therapies are improving patient outcomes by increasing tolerance thresholds and reducing the risk of accidental allergic reactions.

Get In-Depth Knowledge on Peanut Allergy Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/report-store/peanut-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Peanut Allergy Marketed Drugs

• PALFORZIA (peanut allergen powder-dnfp): Stallergenes Greer

PALFORZIA is the first FDA-approved oral immunotherapy for Peanut Allergy, designed to gradually reduce allergic sensitivity through controlled allergen exposure. Despite demonstrating efficacy, treatment adherence challenges and safety concerns continue to impact broader adoption.

• XOLAIR (omalizumab): Roche and Novartis

XOLAIR received FDA approval for reducing allergic reactions, including anaphylaxis, in patients with IgE-mediated food allergy aged one year and older. The therapy represents a significant advancement in Peanut Allergy treatment by targeting and blocking IgE pathways.

Peanut Allergy Emerging Therapies

• Viaskin (DBV712) Peanut Patch: DBV Technologies

Viaskin Peanut utilizes epicutaneous immunotherapy to deliver controlled peanut protein exposure through a wearable patch. The therapy has received both Fast Track and Breakthrough Therapy Designations from the FDA and is currently in Phase III clinical development.

• Remibrutinib (LOU064): Novartis

Remibrutinib is a highly selective oral BTK inhibitor under investigation for Peanut Allergy and other immune-mediated disorders. The therapy is currently being evaluated in Phase II clinical trials.

• PVX108 (AVX-201): Aravax

PVX108 is designed to target T-cell mediated immune responses and potentially reverse allergic disease progression in pediatric Peanut Allergy patients.

Peanut Allergy Drugs Class Analysis

BTK inhibitors represent a promising class of emerging therapies for Peanut Allergy by suppressing mast cell and basophil activation through inhibition of intracellular signaling pathways. These therapies may provide rapid prophylactic protection against allergic reactions and accidental allergen exposure.

Other emerging therapeutic classes include:

• Immunomodulators

• Immunostimulants

• Immunosuppressants

• Cytotoxic T-lymphocyte stimulants combined with IL-13 receptor inhibitors

Peanut Allergy Market Outlook

The Peanut Allergy Treatment Market is expected to undergo substantial transformation during the forecast period owing to increasing disease prevalence, growing awareness, and expanding therapeutic innovation.

The launch of emerging therapies such as Viaskin Peanut Patch, Remibrutinib, and other novel immunotherapies is anticipated to significantly improve treatment accessibility, convenience, and patient outcomes.

Among the 7MM, the United States accounted for the largest Peanut Allergy Treatment Market Size, valued at approximately USD 340 million in 2024.

Viaskin Peanut Patch is expected to emerge as one of the leading non-invasive treatment options for pediatric patients due to its favorable safety profile and convenient administration approach.

Scope of the Peanut Allergy Treatment Market Report

• Coverage: 7MM

• Study Period: 2020–2034

• Forecast Period: 2025–2034

• Geographies Covered: United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan

• Peanut Allergy Companies: DBV Technologies, Novartis, Aravax, ALK-Abello, InnoUp Farma, Allergy Therapeutics, Intrommune Therapeutics, Roche, Regeneron Pharmaceuticals, and others.

• Peanut Allergy Therapies: PALFORZIA, XOLAIR, Viaskin Peanut Patch, Remibrutinib, PVX108, SLIT-Tablet, INP20, INT301, and others.

Unlock Strategic Insights with DelveInsight’s Comprehensive Peanut Allergy Treatment Market Report @ https://www.delveinsight.com/report-store/peanut-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Peanut Allergy Epidemiology and Market Forecast Methodology

5. Peanut Allergy Market Overview at a Glance

6. Disease Background and Overview

7. Peanut Allergy Diagnosis and Treatment Guidelines

8. Epidemiology and Patient Population

9. Peanut Allergy Emerging Therapies

10. Peanut Allergy Market Analysis

11. Peanut Allergy Drugs Uptake

12. Unmet Needs

13. SWOT Analysis

14. KOL Views

15. Market Access and Reimbursement

16. Competitive Intelligence Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm specializing in life sciences and healthcare intelligence. The company provides comprehensive market research reports, epidemiology forecasts, competitive intelligence, and strategic insights to support informed business decisions for pharmaceutical, biotechnology, and healthcare organizations worldwide.

Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email: Send Email
Phone: +919650213330
Address:63, M3M 113 Market, Sector 113
City: Gurugram
State: https://www.delveinsight.com/
Country: India
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peanut Allergy Treatment Market Size in the 7MM was Valued at ~USD 533 Million in 2025 and is Expected to Reach ~USD 2,464 Million by 2034, Growing at a CAGR of 18.50%, Estimates DelveInsight

Tendinopathy Market is Expected to Witness Significant Growth by 2036 Owing to the Emergence of Novel Regenerative Therapies | DelveInsight

The market dynamics for Tendinopathy are witnessing considerable growth driven by increasing prevalence of tendon injuries, rising participation in sports and physical activities, growing aging population, and advancements in regenerative medicine approaches. Additionally, the launch of emerging therapies such as TenoMiR (CWT-001) and other biologic therapies will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Tendinopathy Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Tendinopathy, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Tendinopathy Market

The market size for Tendinopathy in the 7MM was approximately USD 237.58 million in 2022 and is expected to increase significantly by 2036.
The United States accounted for the highest Tendinopathy market size among the 7MM in 2025, compared to EU4 countries, the United Kingdom, and Japan.
Epidemiological data indicate that 898 per 100,000 individuals in the United States are diagnosed with Achilles tendinopathy, with the highest incidence observed in those aged 50–59 years.
As per secondary research, approximately 4.0% of Achilles tendinopathy patients progressed to rupture, highest in the 50–59 years age group (4.3%).
In the UK, Achilles tendon rupture incidence is 0.008–0.018% per annum, with nearly 4,500 patients seeking medical help yearly.
According to a real-world cohort study, the 12-month prevalence of tendon rupture and tendinopathy was 3.4% among patients with atherosclerotic cardiovascular disease and 1.9% in the overall population.
Leading Tendinopathy companies, such as Causeway Therapeutics and New York R&D Center for Translational Medicine and Therapeutics, are developing novel Tendinopathy therapies that are expected to enter the market in the coming years.
The promising Tendinopathy therapies in development include TenoMiR (CWT-001), TenoGen, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/tendinopathy-market

Key Factors Driving the Tendinopathy Market

Rising Prevalence of Tendon Injuries: Increasing participation in sports, fitness activities, and physically demanding occupations is contributing to a growing burden of tendon injuries and chronic tendinopathy cases globally.

Growing Aging Population: Older adults are particularly susceptible to tendinopathy due to age-related tendon degeneration, reduced healing capacity, and repetitive mechanical stress exposure.

Advancements in Regenerative Medicine: Growing research in biologics, platelet-rich plasma (PRP), extracellular shock wave therapy (ESWT), stem cell therapies, and microRNA-based therapies is reshaping the Tendinopathy treatment landscape.

Increasing Awareness and Improved Diagnosis: Enhanced awareness among healthcare providers and advancements in imaging modalities such as ultrasound and MRI are contributing to earlier and more accurate diagnosis of Tendinopathy.

Tendinopathy Competitive Landscape

Several Tendinopathy therapies are under development, led by Causeway Therapeutics’ TenoMiR (CWT-001), along with TenoGen and other regenerative therapies.

These therapies focus on restoring tendon healing pathways, reducing pain, improving tendon structure, and addressing the underlying degenerative pathology rather than providing only symptomatic relief.

Discover more about therapies set to grab major Tendinopathy market share @ Tendinopathy Treatment Landscape

Recent Developments in the Tendinopathy Market

In October 2025, Causeway Therapeutics announced positive Phase II topline data for TenoMiR (CWT-001) in elbow tendinopathy. Correctly injected patients showed significant improvements in pain, function, and tendon structure.
TenoMiR (CWT-001) is an investigational first-in-class microRNA-based therapy designed to restore microRNA-29a levels in injured tendon tissue.
Causeway Therapeutics plans to initiate a Phase III trial of TenoMiR in lateral epicondylitis and a Phase II study in rotator cuff tendinopathy.
In a study involving 90 patients receiving the target dose of TenoMiR or placebo, the therapy demonstrated significant reductions in pain and improvements in upper limb and elbow-specific function at 14, 28, and 90 days.
VergenixSTR, developed by CollPlant, is approved in the EU for treating tendinopathy in various tendons, including elbow, rotator cuff, patellar, Achilles, and hand tendons.

What is Tendinopathy?

Tendinopathy is a chronic musculoskeletal disorder characterized by tendon pain, functional limitation, and structural abnormalities including collagen disorganization, neovascularization, and failed tendon healing. Commonly affected tendons include the Achilles tendon, patellar tendon, rotator cuff, elbow epicondyles, and gluteal tendons. The condition is associated with repetitive mechanical overload, aging, obesity, diabetes, sports injuries, and occupational stress. Diagnosis is primarily clinical and supported by imaging techniques such as ultrasound and MRI in uncertain cases.

Tendinopathy Epidemiology Segmentation

The Tendinopathy epidemiology section provides insights into the historical and current Tendinopathy patient pool and forecasted trends for the 7MM. The Tendinopathy market report proffers epidemiological analysis for the study period 2022–2036 segmented into:

Total Incident Cases of Tendinopathy
Gender-specific Cases of Tendinopathy
Age-specific Cases of Tendinopathy
Region-specific Cases of Tendinopathy
Total Treated Cases of Tendinopathy

Scope of the Tendinopathy Market Report

Therapeutic Assessment: Tendinopathy current marketed and emerging therapies
Tendinopathy Market Dynamics: Key Market Forecast Assumptions of Emerging Tendinopathy Drugs and Market Outlook
Key Companies: Causeway Therapeutics, New York R&D Center for Translational Medicine and Therapeutics, CollPlant, and others
Key Therapies: TenoMiR (CWT-001), TenoGen, PRP Therapy, VergenixSTR, ESWT, Glyceryl Trinitrate, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Tendinopathy Market Access and Reimbursement

To know more about Tendinopathy companies working in the treatment market, visit @ Tendinopathy Clinical Trials and Therapeutic Assessment

Table of Contents

Tendinopathy Market Report Introduction
Executive Summary for Tendinopathy
SWOT Analysis of Tendinopathy
Tendinopathy Patient Share (%) Overview at a Glance
Tendinopathy Market Overview at a Glance
Tendinopathy Background and Overview
Tendinopathy Epidemiology and Patient Population
Country-Specific Patient Population of Tendinopathy
Tendinopathy Current Treatment and Medical Practices
Tendinopathy Unmet Needs
Tendinopathy Emerging Therapies
Tendinopathy Market Outlook
Country-Wise Tendinopathy Market Analysis (2022–2036)
Tendinopathy Market Access and Reimbursement of Therapies
Tendinopathy Market Drivers
Tendinopathy Market Barriers
Tendinopathy Appendix
Tendinopathy Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tendinopathy Market is Expected to Witness Significant Growth by 2036 Owing to the Emergence of Novel Regenerative Therapies | DelveInsight

Obesity Market is Expected to Witness Significant Growth by 2036 Due to Advancements in GLP-1 Therapies and Expanding Treatment Accessibility | DelveInsight

The obesity market is experiencing substantial transformation driven by the rising global obesity burden, growing awareness regarding obesity as a chronic disease, increasing adoption of GLP-1 receptor agonists, and the emergence of next-generation metabolic therapies. The anticipated launch of innovative therapies such as Retatrutide, Survodutide, CagriSema, VK2735, and Amycretin is expected to further accelerate market growth across the 7MM during the forecast period.

DelveInsight, a leading business consulting and market research company, has released its latest report, “Obesity Market Insight, Epidemiology, and Market Forecast – 2036,” providing comprehensive insights into obesity epidemiology, treatment practices, marketed and emerging therapies, and market dynamics across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Obesity Market Report

The obesity market in the 7MM is projected to grow substantially by 2036 due to expanding use of incretin-based therapies and increasing treatment uptake.
DelveInsight estimates that the obesity market size in the 7MM was approximately USD 16 billion in 2025 and is anticipated to increase significantly through 2036.
According to DelveInsight’s analysis, the United States represented approximately 60% of the total prevalent obesity cases across the 7MM in 2025.
In the US, around 5.5 million children aged 5–19 years were living with obesity in 2025.
Germany reported approximately 18 million prevalent obesity cases in 2025, representing the highest disease burden among EU4 and the UK.
Existing marketed therapies include WEGOVY, ZEPBOUND, SAXENDA, CONTRAVE/MYSIMBA, and QYSMIA.
WEGOVY and ZEPBOUND continue to dominate the obesity treatment landscape owing to their strong efficacy profiles and expanding global approvals.
In April 2026, Eli Lilly announced that the US FDA approved FOUNDAYO (orforglipron) for adults with obesity or overweight and weight-related comorbidities.
Emerging therapies including Retatrutide, Survodutide, CagriSema, VK2735, Amycretin, MariTide, CT-388, and Pemvidutide are expected to reshape future obesity management.
The obesity pipeline is highly competitive, with several therapies in Phase III clinical development demonstrating promising efficacy and metabolic benefits.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market

Key Factors Driving the Obesity Market

Increasing Global Obesity Burden

Rising prevalence of obesity among adults and children continues to fuel demand for effective long-term treatment strategies. Sedentary lifestyles, dietary changes, and metabolic disorders are contributing significantly to disease growth worldwide.

Growing Adoption of GLP-1 and Dual/Triple Agonist Therapies

The success of GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Therapies targeting GLP-1, GIP, and glucagon receptors are delivering unprecedented weight reduction outcomes compared to older therapies.

Expanding Awareness of Obesity as a Chronic Disease

Healthcare systems and medical societies increasingly recognize obesity as a chronic metabolic disease associated with major comorbidities including cardiovascular disease, diabetes, hypertension, and sleep apnea, driving greater treatment adoption.

Advancements in Precision and Combination Therapies

Emerging personalized approaches and multi-target metabolic therapies are improving efficacy, metabolic control, and long-term treatment outcomes while expanding therapeutic options for patients.

Obesity Competitive Landscape

The obesity market is currently dominated by incretin-based therapies such as WEGOVY (semaglutide) and ZEPBOUND (tirzepatide), which have demonstrated substantial weight loss efficacy and growing physician adoption globally.

Key Marketed Therapies

WEGOVY (semaglutide) – Novo Nordisk
ZEPBOUND (tirzepatide) – Eli Lilly
SAXENDA (liraglutide) – Novo Nordisk
CONTRAVE/MYSIMBA (naltrexone-bupropion)
QYSMIA (phentermine-topiramate)

Emerging Therapies in Development

Survodutide (BI 456906) – Boehringer Ingelheim
Retatrutide – Eli Lilly
CagriSema – Novo Nordisk
VK2735 – Viking Therapeutics
Amycretin – Novo Nordisk
Pemvidutide (ALT-801) – Altimmune
MariTide – Amgen
CT-388 – Carmot Therapeutics/Roche
FOUNDAYO (orforglipron) – Eli Lilly
RGT-075 – Regor Therapeutics

These emerging therapies are expected to intensify competition and expand treatment accessibility over the forecast period.

Discover more about therapies set to grab major Obesity Market share @ Obesity Market Landscape

Recent Developments in the Obesity Market

In April 2026, Eli Lilly announced US FDA approval of FOUNDAYO (orforglipron) for obesity and overweight patients with weight-related comorbidities.
In January 2026, Novo Nordisk announced broad US availability of oral WEGOVY, the first oral GLP-1 therapy approved for weight loss.
In December 2025, Novo Nordisk submitted an NDA to the US FDA for CagriSema for chronic weight management.
In September 2025, Regeneron reported positive interim Phase II COURAGE trial data evaluating semaglutide combinations for obesity treatment.
Orforglipron demonstrated significant weight loss and cardiometabolic benefits in the ATTAIN-1 study published in The New England Journal of Medicine.

What is Obesity?

Obesity is a chronic, multifactorial, non-communicable disease characterized by excessive adiposity or body fat accumulation that adversely impacts health. It results primarily from an imbalance between energy intake and energy expenditure, influenced by environmental, psychosocial, metabolic, and genetic factors.

Diagnosis is generally based on Body Mass Index (BMI), calculated as weight in kilograms divided by height squared in meters. Obesity is associated with increased risks of cardiovascular disease, diabetes, hypertension, sleep apnea, metabolic syndrome, and several other chronic disorders.

Obesity Epidemiology Segmentation

The obesity epidemiology section in the report provides historical and forecasted data across the 7MM from 2022–2036, segmented into:

Total Prevalent Cases of Obesity
Adult Obesity Cases
Childhood Obesity Cases
Total Treated Cases of Obesity
Country-specific Obesity Burden
Patients Seeking Treatment
Therapy-specific Treated Population

Scope of the Obesity Market Report

Comprehensive overview of obesity pathophysiology and treatment landscape
Historical and forecasted obesity market size analysis
Epidemiology segmentation across the 7MM
Assessment of marketed and emerging therapies
Competitive landscape and pipeline analysis
Market drivers, barriers, SWOT, and unmet needs
KOL perspectives and analyst insights
Market access and reimbursement analysis

To know more about Obesity companies working in the treatment market, visit @ Obesity Clinical Trials and Therapeutic Assessment

Table of Contents

Key Insights
Report Introduction
Executive Summary
Key Events
Epidemiology and Market Forecast Methodology
Obesity Market Overview at a Glance
Disease Background and Overview
Diagnosis
Treatment and Management
Epidemiology and Patient Population
Patient Journey
Marketed Therapies
Emerging Therapies
Obesity Market Analysis
KOL Views
SWOT Analysis
Unmet Needs
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

DelveInsight is a leading business consulting and market research company focused exclusively on life sciences. The company provides comprehensive market intelligence, epidemiology forecasting, pipeline analysis, and strategic consulting services to pharmaceutical and biotechnology companies worldwide.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Market is Expected to Witness Significant Growth by 2036 Due to Advancements in GLP-1 Therapies and Expanding Treatment Accessibility | DelveInsight

Hereditary Angioedema (HAE) Market is Expected to Witness Significant Growth by 2036 Owing to the Launch of Novel Therapies | DelveInsight

The market dynamics for Hereditary Angioedema (HAE) are witnessing considerable growth driven by increasing awareness and diagnosis rates, advancements in prophylactic and on-demand therapies, and the emergence of novel gene-editing and RNA-targeted therapies. Additionally, the launch of emerging therapies such as ADX-324 (ADARx Pharmaceuticals), Lonvoguran ziclumeran/NTLA-2002 (Intellia Therapeutics), Navenibart (Astria Therapeutics), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Hereditary Angioedema (HAE) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of HAE, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Hereditary Angioedema (HAE) Market

The market size for Hereditary Angioedema (HAE) in the leading markets is expected to grow significantly by 2036.
The United States accounted for the highest HAE treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
As per DelveInsight’s assessment, the total diagnosed prevalent cases of HAE in the 7MM in 2025 were ~14,500, which are expected to increase by 2036 at a considerable CAGR.
Among the 7MM, the US accounted for the highest prevalent cases of HAE in 2025, while Japan accounted for the least number of prevalent cases.
The type-specific diagnosed prevalent cases of HAE are categorized into Type I, Type II, and HAE with normal C1-INH (Type III). Among these, Type I HAE accounted for the highest cases in the 7MM in 2025.
According to Hide et al. (2021), the estimated number of patients with Type I HAE and Type II HAE in Japan is 2,000–3,000, though only 450 patients have received a formal diagnosis to date.
Approximately 40% of HAE attacks go untreated, even among patients on prophylaxis. More attacks could be addressed effectively for both prophylaxis and on-demand patients.
Leading HAE companies, such as ADARx Pharmaceuticals, Intellia Therapeutics, Astria Therapeutics, CSL Behring, Takeda, BioCryst Pharmaceuticals, Pharvaris, and others, are developing new HAE treatment drugs that can be available in the HAE market in the coming years.
The promising HAE therapies in clinical trials include ADX-324, NTLA-2002, Navenibart (STAR-0215), deucrictibant, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/hereditary-angioedema-market

Key Factors Driving the Hereditary Angioedema (HAE) Market

Increasing Awareness and Diagnosis Rates: Growing awareness regarding rare genetic diseases and improved diagnostic testing are leading to earlier and more accurate diagnosis of HAE. Enhanced physician education and patient advocacy initiatives are also contributing to market growth.

Rising Demand for Long-term Prophylactic Therapies: The increasing adoption of prophylactic therapies such as TAKHZYRO, HAEGARDA, ANDEMBRY, and ORLADEYO is significantly reducing disease burden and improving quality of life for HAE patients.

Advancements in Novel Therapeutic Approaches: Emerging therapies, including RNA-targeted therapies, monoclonal antibodies, oral kallikrein inhibitors, and gene-editing approaches, are expected to revolutionize HAE treatment by providing long-lasting disease control and potentially curative outcomes.

Hereditary Angioedema (HAE) Competitive Landscape

Several HAE drugs in development include ADX-324 (ADARx Pharmaceuticals), Lonvoguran ziclumeran/NTLA-2002 (Intellia Therapeutics), Navenibart (STAR-0215) (Astria Therapeutics), deucrictibant (Pharvaris), and others.

These candidates target diverse mechanisms such as plasma kallikrein inhibition, factor XIIa inhibition, RNA-targeted therapies, and CRISPR-based gene editing aimed at reducing HAE attack frequency and improving patient convenience with less frequent dosing and self-administration options.

Discover more about therapies set to grab major Hereditary Angioedema (HAE) market share @ Hereditary Angioedema (HAE) Treatment Landscape

Recent Developments in the Hereditary Angioedema (HAE) Market

In October 2025, ADARx Pharmaceuticals announced that the first patient has been dosed in its Phase III STOP-HAE clinical trial evaluating ADX-324 in patients with HAE.
In November 2025, Intellia Therapeutics announced interim Phase I/II clinical data showing dramatic reductions in attack rate, as well as consistent, deep, and durable reductions in kallikrein levels with NTLA-2002.
In January 2026, Intellia Therapeutics announced that Phase III results of the HAELO trial for NTLA-2002 are expected by mid-2026, with BLA submission planned for H2 2026 and a potential market launch expected in 2027.
In February 2025, Astria Therapeutics initiated the ALPHA-ORBIT Phase III pivotal trial of Navenibart in HAE.
In July 2025, the US FDA approved sebetralstat (EKTERLY), the first and only oral on-demand treatment for HAE in adult and pediatric patients aged 12 years and older.
In August 2025, the US FDA approved donidalorsen (DAWNZERA), the first RNA-targeted treatment for HAE.

What is Hereditary Angioedema (HAE)?

Hereditary Angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling affecting various parts of the body, including the extremities, gastrointestinal tract, face, and airway. The disease is primarily caused by mutations affecting C1 esterase inhibitor (C1-INH), leading to excessive bradykinin production and increased vascular permeability. HAE attacks can be painful, debilitating, and potentially life-threatening when airway swelling occurs.

Hereditary Angioedema (HAE) Epidemiology Segmentation

The HAE epidemiology section provides insights into the historical and current HAE patient pool and forecasted trends for the leading markets. The HAE market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

Total Diagnosed Prevalent Cases of HAE
Type-specific Diagnosed Prevalent Cases of HAE
Gender-specific Diagnosed Prevalent Cases of HAE
Age-specific Diagnosed Prevalent Cases of HAE

Scope of the Hereditary Angioedema (HAE) Market Report

Therapeutic Assessment: HAE current marketed and emerging therapies
HAE Market Dynamics: Key Market Forecast Assumptions of Emerging HAE Drugs and Market Outlook
Key Companies: ADARx Pharmaceuticals, Intellia Therapeutics, Astria Therapeutics, CSL Behring, Takeda, BioCryst Pharmaceuticals, Pharvaris, and others
Key Therapies: ADX-324, NTLA-2002, Navenibart (STAR-0215), deucrictibant, TAKHZYRO, HAEGARDA, ORLADEYO, ANDEMBRY, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, HAE Market Access and Reimbursement

To know more about Hereditary Angioedema (HAE) companies working in the treatment market, visit @ Hereditary Angioedema (HAE) Clinical Trials and Therapeutic Assessment

Table of Contents

Hereditary Angioedema (HAE) Market Report Introduction
Executive Summary for HAE
SWOT Analysis of HAE
HAE Patient Share (%) Overview at a Glance
HAE Market Overview at a Glance
HAE Background and Overview
HAE Epidemiology and Patient Population
Country-Specific Patient Population of HAE
HAE Current Treatment and Medical Practices
HAE Unmet Needs
HAE Emerging Therapies
HAE Market Outlook
Country-Wise HAE Market Analysis (2022–2036)
HAE Market Access and Reimbursement of Therapies
HAE Market Drivers
HAE Market Barriers
HAE Appendix
HAE Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hereditary Angioedema (HAE) Market is Expected to Witness Significant Growth by 2036 Owing to the Launch of Novel Therapies | DelveInsight

Adrenoleukodystrophy Market is Expected to Witness Significant Growth by 2036 Owing to the Emergence of Gene and Metabolic-targeted Therapies | DelveInsight

The market dynamics for Adrenoleukodystrophy (ALD) are witnessing steady growth driven by the increasing adoption of newborn screening programs, growing awareness regarding rare neurodegenerative disorders, advancements in gene therapy approaches, and rising focus on disease-modifying treatments. Additionally, the launch of emerging therapies such as Leriglitazone (MIN-102) (Minoryx Therapeutics and Neuraxpharm), VK0214 (Viking Therapeutics), PXL065 (Poxel), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Adrenoleukodystrophy Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Adrenoleukodystrophy, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Adrenoleukodystrophy Market

The market size for Adrenoleukodystrophy in the leading markets is expected to grow significantly by 2036.
The United States accounted for the highest Adrenoleukodystrophy treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
DelveInsight’s analysis indicates that the total prevalent cases of ALD in the 7MM were approximately 57,000 cases in 2025.
According to DelveInsight’s analysis, the total number of prevalent cases of ALD in the US in 2025 was nearly 21,000, while diagnosed cases were around 6,000.
According to studies cited in the report, ALD affects approximately 1 in 20,000 to 1 in 50,000 individuals worldwide, while newborn incidence is estimated at around 1 in 50,000 births.
Leading Adrenoleukodystrophy companies, such as Genetix Biotherapeutics, Minoryx Therapeutics, Viking Therapeutics, Poxel, Neuraxpharm, and others, are developing new Adrenoleukodystrophy treatment drugs that can be available in the Adrenoleukodystrophy market in the coming years.
The promising Adrenoleukodystrophy therapies in clinical trials include Leriglitazone (MIN-102), VK0214, PXL065, PXL770, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/adrenoleukodystrophy-market

Key Factors Driving the Adrenoleukodystrophy Market

Increasing Adoption of Newborn Screening Programs:

Expanding newborn screening programs across multiple regions are enabling earlier diagnosis of ALD, allowing timely MRI monitoring and therapeutic intervention before irreversible neurological damage occurs. Early detection is significantly improving treatment outcomes in patients with cerebral ALD.

Growing Advancements in Gene and Cell-based Therapies:

Gene and cell-based therapies such as SKYSONA are transforming the treatment landscape for patients with early cerebral ALD, especially for individuals lacking a suitable donor for hematopoietic stem cell transplantation (HSCT). The growing success of gene therapy approaches is increasing confidence in disease-modifying treatment strategies.

Rising Focus on Emerging Metabolic-targeted Therapies:

Several investigational therapies targeting metabolic dysfunction, neuroinflammation, mitochondrial pathways, and VLCFA metabolism are being evaluated in clinical trials. Emerging therapies such as Leriglitazone and VK0214 are expected to significantly improve treatment options for adult adrenomyeloneuropathy (AMN) patients.

Adrenoleukodystrophy Competitive Landscape

Several Adrenoleukodystrophy drugs in development include Leriglitazone (MIN-102) (Minoryx Therapeutics and Neuraxpharm), VK0214 (Viking Therapeutics), PXL065 and PXL770 (Poxel), and others.

These candidates target diverse mechanisms such as PPAR-γ agonism (Leriglitazone), thyroid hormone receptor-β activation (VK0214), mitochondrial pyruvate carrier modulation (PXL065), and AMPK activation (PXL770), aiming to reduce VLCFA accumulation, improve mitochondrial metabolism, and slow neurological progression in ALD patients.

Discover more about therapies set to grab major Adrenoleukodystrophy market share @ Adrenoleukodystrophy Treatment Landscape

Recent Developments in the Adrenoleukodystrophy Market

In July 2025, Minoryx Therapeutics and Neuraxpharm announced that the Marketing Authorization Application (MAA) for Leriglitazone (NEZGLYAL) for cerebral ALD was validated by the European Medicines Agency and is currently under CHMP review.
In August 2025, the US FDA required updated safety labeling for SKYSONA after reports of hematologic malignancies were observed in treated patients, reinforcing long-term monitoring requirements.
In October 2024, Viking Therapeutics announced positive Phase Ib clinical trial results for VK0214 in patients with X-linked ALD, demonstrating significant reductions in VLCFA levels.
In December 2022, Poxel announced that PXL065 received Fast Track Designation from the US FDA for adrenomyeloneuropathy associated with X-linked ALD, followed by Orphan Drug Designation in 2023.

What is Adrenoleukodystrophy?

Adrenoleukodystrophy (ALD) is a rare, X-linked genetic neurodegenerative disorder caused by mutations in the ABCD1 gene, resulting in the accumulation of very-long-chain fatty acids (VLCFAs) in the body. The disease progressively damages the brain, spinal cord, and adrenal glands, leading to severe neurological impairment and adrenal insufficiency. ALD presents in multiple phenotypes, including childhood cerebral ALD, adrenomyeloneuropathy (AMN), and Addison disease. Symptoms may include behavioral changes, vision and hearing loss, seizures, impaired motor function, and progressive neurological decline.

Adrenoleukodystrophy Epidemiology Segmentation

The Adrenoleukodystrophy epidemiology section provides insights into the historical and current Adrenoleukodystrophy patient pool and forecasted trends for the leading markets. The Adrenoleukodystrophy market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

Total Prevalent Cases of Adrenoleukodystrophy
Total Diagnosed Prevalent Cases of Adrenoleukodystrophy
Gender-specific Diagnosed Prevalent Cases of Adrenoleukodystrophy
Stage-specific Diagnosed Prevalent Cases of Adrenoleukodystrophy

Scope of the Adrenoleukodystrophy Market Report

Therapeutic Assessment: Adrenoleukodystrophy current marketed and emerging therapies
Adrenoleukodystrophy Market Dynamics: Key Market Forecast Assumptions of Emerging Adrenoleukodystrophy Drugs and Market Outlook
Key Companies: Genetix Biotherapeutics, Minoryx Therapeutics, Viking Therapeutics, Poxel, Neuraxpharm, and others
Key Therapies: SKYSONA, Leriglitazone (MIN-102), VK0214, PXL065, PXL770, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Adrenoleukodystrophy Market Access and Reimbursement

To know more about Adrenoleukodystrophy companies working in the treatment market, visit @ Adrenoleukodystrophy Clinical Trials and Therapeutic Assessment

Table of Contents

Adrenoleukodystrophy Market Report Introduction
Executive Summary for Adrenoleukodystrophy
SWOT Analysis of Adrenoleukodystrophy
Adrenoleukodystrophy Patient Share (%) Overview at a Glance
Adrenoleukodystrophy Market Overview at a Glance
Adrenoleukodystrophy Background and Overview
Adrenoleukodystrophy Epidemiology and Patient Population
Country-Specific Patient Population of Adrenoleukodystrophy
Adrenoleukodystrophy Current Treatment and Medical Practices
Adrenoleukodystrophy Unmet Needs
Adrenoleukodystrophy Emerging Therapies
Adrenoleukodystrophy Market Outlook
Country-Wise Adrenoleukodystrophy Market Analysis (2022–2036)
Adrenoleukodystrophy Market Access and Reimbursement of Therapies
Adrenoleukodystrophy Market Drivers
Adrenoleukodystrophy Market Barriers
Adrenoleukodystrophy Appendix
Adrenoleukodystrophy Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adrenoleukodystrophy Market is Expected to Witness Significant Growth by 2036 Owing to the Emergence of Gene and Metabolic-targeted Therapies | DelveInsight

Alpha-1 Antitrypsin Deficiency Market is Anticipated to Expand Rapidly by 2034 Owing to the Emergence of Innovative Gene and RNA-based Therapies | DelveInsight

The market dynamics for Alpha-1 Antitrypsin Deficiency (AATD) are witnessing steady growth driven by the increasing prevalence of respiratory and liver diseases associated with AATD, rising awareness and diagnosis rates, and growing advancements in gene-editing and RNA-based therapies. Additionally, the launch of emerging therapies such as Fazirsiran (ARO-AAT/TAK-999), Inhaled Alpha 1-Antitrypsin (AAT), Alvelestat (MPH-966), WVE-006, KB408, and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Alpha-1 Antitrypsin Deficiency (AATD) Market Insights, Epidemiology, and Market Forecast 2034.” This comprehensive report provides an in-depth understanding of Alpha-1 Antitrypsin Deficiency, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Alpha-1 Antitrypsin Deficiency Market

The market size for Alpha-1 Antitrypsin Deficiency in the leading markets is expected to grow significantly by 2034.
The United States accounted for the highest Alpha-1 Antitrypsin Deficiency treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
Based on DelveInsight’s assessment in 2024, the 7MM had approximately 225,950 prevalent cases of AATD, which are expected to rise during the forecast period (2025–2034).
According to DelveInsight’s analysis, the number of prevalent cases of AATD in the US was estimated to be nearly 134,340 in 2024.
Data suggests that the majority of AATD patients remain undiagnosed, with nearly 90% of cases being missed, while only 5–10% of patients receive a confirmed diagnosis.
In 2024, Japan accounted for approximately 2,950 cases of AATD, with prevalence significantly lower compared to the US and Europe.
Leading Alpha-1 Antitrypsin Deficiency companies, such as Kamada Pharmaceuticals, Arrowhead Pharmaceuticals and Takeda, Mereo BioPharma/AstraZeneca, Sanofi/Inhibrx Biosciences, Wave Life Sciences, Beam Therapeutics, Grifols, Krystal Biotech, BioMarin, AlveoGene, Korro Bio, Spexis/Santhera Pharmaceutical, and others, are developing new Alpha-1 Antitrypsin Deficiency treatment drugs that can be available in the Alpha-1 Antitrypsin Deficiency market in the coming years.
The promising Alpha-1 Antitrypsin Deficiency therapies in clinical trials include Fazirsiran (ARO-AAT/TAK-999), Inhaled Alpha 1-Antitrypsin (AAT), Alvelestat (MPH-966), INBRX-101/SAR447537, WVE-006, KB408, BEAM-302, Alpha-1 AT 15%, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-a1atd-market

Key Factors Driving the Alpha-1 Antitrypsin Deficiency Market

Rising Awareness and Diagnosis Rates:

Increasing awareness among healthcare professionals and the growing use of genetic and biomarker-based diagnostic testing are improving the diagnosis of AATD. Enhanced screening for patients with COPD, emphysema, and liver disorders is expected to contribute to market growth.

Growing Advancements in Gene and RNA-based Therapies:

Emerging therapies targeting the root cause of AATD through RNA interference, RNA editing, gene correction, and inhaled protein replacement approaches are transforming the treatment landscape. Therapies such as Fazirsiran, WVE-006, and BEAM-302 are attracting significant market attention due to their potential disease-modifying and curative capabilities.

Increasing Demand for Improved and Convenient Treatment Approaches:

Current augmentation therapies require frequent intravenous administration and are associated with high treatment burden. New inhaled, oral, subcutaneous, and self-administered therapies are expected to improve patient compliance, convenience, and quality of life.

Alpha-1 Antitrypsin Deficiency Competitive Landscape

Several Alpha-1 Antitrypsin Deficiency drugs in development include Fazirsiran (ARO-AAT/TAK-999) (Arrowhead Pharmaceuticals and Takeda), Inhaled Alpha 1-Antitrypsin (AAT) (Kamada Pharmaceuticals), Alvelestat (MPH-966) (Mereo BioPharma/AstraZeneca), INBRX-101/SAR447537 (Sanofi/Inhibrx Biosciences), WVE-006 (Wave Life Sciences), KB408 (Krystal Biotech), and BEAM-302 (Beam Therapeutics).

These candidates target diverse mechanisms such as reduction of mutant Z-AAT protein production, immunomodulation through inhaled AAT replacement, neutrophil elastase inhibition, RNA editing, and gene correction technologies, aiming to provide long-term disease modification with improved efficacy and convenience compared to current augmentation therapies.

Discover more about therapies set to grab major Alpha-1 Antitrypsin Deficiency market share @ Alpha-1 Antitrypsin Deficiency Treatment Landscape

Recent Developments in the Alpha-1 Antitrypsin Deficiency Market

In March 2025, the FDA approved an update to GLASSIA’s US Prescribing Information to include 1-, 4-, and 5-gram single-dose vials, available from July 2025, aiming to simplify weight-based dosing and improve convenience for patients.
In November 2024, Korro Bio announced submission to the Bellberry HREC for a Phase I/II clinical study of KRRO-110 for AATD.
In October 2024, Wave Life Sciences highlighted proof-of-mechanism data for WVE-006 for the treatment of AATD during Annual Research Day 2024.
In September 2024, Krystal Biotech amended the protocol for its KB408 Phase I SERPENTINE-1 study to include mandatory bronchoscopies for measuring alpha-1 antitrypsin expression.
In July 2024, Beam Therapeutics entered into a settlement agreement related to BEAM-302 development and commercialization activities.
According to Takeda’s FY2024 presentation released in May 2025, the company anticipates regulatory submissions for Fazirsiran in AATD-related liver disease between 2027 and 2029.

What is Alpha-1 Antitrypsin Deficiency?

Alpha-1 Antitrypsin Deficiency (AATD) is a rare inherited genetic disorder caused by mutations in the SERPINA1 gene, leading to low levels or dysfunctional alpha-1 antitrypsin protein in the blood. The condition primarily affects the lungs and liver, resulting in diseases such as emphysema, chronic obstructive pulmonary disease (COPD), cirrhosis, and liver failure. AATD is often underdiagnosed because its symptoms resemble those of asthma, COPD, and other liver disorders. Early diagnosis and appropriate management are essential to improve patient outcomes and quality of life.

Alpha-1 Antitrypsin Deficiency Epidemiology Segmentation

The Alpha-1 Antitrypsin Deficiency epidemiology section provides insights into the historical and current Alpha-1 Antitrypsin Deficiency patient pool and forecasted trends for the leading markets. The Alpha-1 Antitrypsin Deficiency market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

Total Prevalent Cases of Alpha-1 Antitrypsin Deficiency
Total Diagnosed Prevalent Cases of Alpha-1 Antitrypsin Deficiency
Genotype-specific Cases of Alpha-1 Antitrypsin Deficiency
Comorbidity-associated Cases of Alpha-1 Antitrypsin Deficiency

Scope of the Alpha-1 Antitrypsin Deficiency Market Report

Therapeutic Assessment: Alpha-1 Antitrypsin Deficiency current marketed and emerging therapies
Alpha-1 Antitrypsin Deficiency Market Dynamics: Key Market Forecast Assumptions of Emerging Alpha-1 Antitrypsin Deficiency Drugs and Market Outlook
Key Companies: Kamada Pharmaceuticals, Arrowhead Pharmaceuticals and Takeda, Mereo BioPharma/AstraZeneca, Sanofi/Inhibrx Biosciences, Wave Life Sciences, Beam Therapeutics, Grifols, Krystal Biotech, BioMarin, AlveoGene, Korro Bio, Spexis/Santhera Pharmaceutical, and others
Key Therapies: Fazirsiran (ARO-AAT/TAK-999), Inhaled Alpha 1-Antitrypsin (AAT), Alvelestat (MPH-966), INBRX-101/SAR447537, WVE-006, KB408, BEAM-302, Alpha-1 AT 15%, PROLASTIN-C LIQUID/LYNSPAD, ZEMAIRA/RESPREEZA, GLASSIA, ARALAST NP, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Alpha-1 Antitrypsin Deficiency Market Access and Reimbursement

To know more about Alpha-1 Antitrypsin Deficiency companies working in the treatment market, visit @ Alpha-1 Antitrypsin Deficiency Clinical Trials and Therapeutic Assessment

Table of Contents

Alpha-1 Antitrypsin Deficiency Market Report Introduction
Executive Summary for Alpha-1 Antitrypsin Deficiency
SWOT Analysis of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency Patient Share (%) Overview at a Glance
Alpha-1 Antitrypsin Deficiency Market Overview at a Glance
Alpha-1 Antitrypsin Deficiency Background and Overview
Alpha-1 Antitrypsin Deficiency Epidemiology and Patient Population
Country-Specific Patient Population of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency Current Treatment and Medical Practices
Alpha-1 Antitrypsin Deficiency Unmet Needs
Alpha-1 Antitrypsin Deficiency Emerging Therapies
Alpha-1 Antitrypsin Deficiency Market Outlook
Country-Wise Alpha-1 Antitrypsin Deficiency Market Analysis (2020–2034)
Alpha-1 Antitrypsin Deficiency Market Access and Reimbursement of Therapies
Alpha-1 Antitrypsin Deficiency Market Drivers
Alpha-1 Antitrypsin Deficiency Market Barriers
Alpha-1 Antitrypsin Deficiency Appendix
Alpha-1 Antitrypsin Deficiency Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alpha-1 Antitrypsin Deficiency Market is Anticipated to Expand Rapidly by 2034 Owing to the Emergence of Innovative Gene and RNA-based Therapies | DelveInsight

Basal Cell Nevus Syndrome (BCNS) Therapeutics Market Expected to Witness Significant Growth Through 2034, estimates DelveInsight

DelveInsight’s “Basal Cell Nevus Syndrome (BCNS) – Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of BCNS, historical and forecasted epidemiology as well as the BCNS market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Takeaways from the Basal Cell Nevus Syndrome Market Report

According to DelveInsight’s estimates, BCNS affects approximately 1 in 31,000 people in the United States, with estimated prevalence in Europe ranging between 1 in 31,000 and 1 in 164,000 individuals, and birth prevalence in the UK reported at 1 in 19,000.
Basal cell carcinomas (BCCs) are the primary feature of Gorlin syndrome, typically developing between puberty and 35 years of age, with an incidence increasing with age and found in 50–97% of cases.
BCNS predominantly presents with multiple odontogenic keratocysts (present in approximately 75% of cases), bifid ribs (seen in 40%), palmar and plantar pits (occurring in 60–90%), and ectopic calcification of the falx cerebri (observed in 37–79%).
The leading BCNS Companies include Ono Pharmaceuticals, Bristol Myers Squibb, Jazz Pharmaceuticals, Sol-Gel Technologies, Inhibitor Therapeutics, and others.
Promising BCNS Pipeline Therapies include SGT-610 (Patidegib Gel 2%), SUBA-Itraconazole, ONO-4538, and ONC206.
According to Sol-Gel Technologies, if approved, SGT-610 would be the first product indicated for the prevention of new BCC lesions in patients with Gorlin syndrome, with potential peak annual revenue projected to exceed USD 300 million.

Stay ahead in the Basal Cell Nevus Syndrome Therapeutics Market with DelveInsight’s Strategic Report @https://www.delveinsight.com/sample-request/basal-cell-nevus-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Basal Cell Nevus Syndrome Epidemiology Segmentation in the 7MM

Total Diagnosed Prevalent Cases of BCNS
Age-specific Cases of BCNS
Clinical Manifestation Distribution of BCNS
Total Treatable Cases of BCNS

Download the report to understand which factors are driving BCNS Epidemiology trends @https://www.delveinsight.com/sample-request/basal-cell-nevus-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Basal Cell Nevus Syndrome Marketed Drugs

Current Treatment Approaches: The current treatment landscape for BCNS is dominated by surgical excision, which remains the mainstay for basal cell carcinomas and jaw keratocysts, with care to preserve function and appearance. Off-label use of Hedgehog pathway inhibitors such as vismodegib and sonidegib, which are FDA-approved for advanced basal cell carcinoma, are widely used in patients with multiple basal cell carcinomas associated with Gorlin syndrome. Regular dermatologic surveillance and imaging are essential to monitor for new tumors, jaw cysts, and skeletal or visceral anomalies.

Basal Cell Nevus Syndrome Emerging Drugs

SGT-610 (Patidegib Gel 2%): Sol-Gel Technologies

SGT-610 is a topical hedgehog signaling pathway blocker with the potential to be the first-ever treatment specifically indicated for Gorlin syndrome. Patidegib, the active substance in SGT-610, is designed to block the SMO signal, allowing cells to function normally and reducing the production of new tumors. The drug is designed to minimize systemic exposure and associated toxicities while effectively reducing tumor burden. According to the company’s Q2 update, top-line results of the Phase III trial of SGT-610 are expected in the fourth quarter of 2026. In January 2023, Sol-Gel Technologies announced the acquisition of topically-applied patidegib for the treatment of Gorlin syndrome from PellePharm.

SUBA-Itraconazole: Inhibitor Therapeutics

SUBA-Itraconazole is a novel formulation of itraconazole with improved bioavailability, currently in Phase II clinical development for individuals with BCNS. The therapy is being explored for its potential Hedgehog pathway inhibition and anti-tumor activity in Gorlin syndrome. In August 2024, Inhibitor Therapeutics provided an update on development efforts for its itraconazole formulation for the treatment of basal cell carcinomas in patients with BCNS. In May 2024, the company formally requested a Type-B, pre-investigational new drug application meeting with the FDA to obtain feedback on the overall drug development and regulatory plan.

To learn more about BCNS treatment guidelines, visit @https://www.delveinsight.com/sample-request/basal-cell-nevus-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Basal Cell Nevus Syndrome Competitive Landscape

The competitive landscape of the BCNS market is characterized by the presence of established pharmaceutical companies and emerging innovators focused on developing targeted therapies to address the underlying PTCH1/Hedgehog pathway abnormalities. The lack of FDA-approved therapies for Gorlin syndrome has led to widespread off-label use of Hedgehog pathway inhibitors, exposing patients to potential toxicity and limited long-term safety data. Market competition is driven by advancements in targeted topical treatments and next-generation SMO inhibitors that are better suited for long-term, chronic use with lower systemic toxicity. Companies are actively investing in research collaborations, pipeline expansion, and regulatory advancements to strengthen their market position and address the significant unmet needs associated with BCNS treatment, particularly for pediatric populations who cannot tolerate systemic therapies due to teratogenicity and growth-related safety concerns.

Basal Cell Nevus Syndrome Market Outlook

Basal Cell Nevus Syndrome, also known as Gorlin syndrome, is a rare, inherited genetic disorder characterized by the development of multiple basal cell carcinomas, jaw keratocysts, and distinctive skeletal abnormalities. It is caused primarily by mutations in the PTCH1 gene, which is part of the Hedgehog signaling pathway, leading to abnormal cell growth and tumor predisposition. Management involves regular dermatologic surveillance, surgical intervention for tumors, and monitoring for other systemic manifestations, with a focus on early detection and prevention of complications. Despite current treatment options, significant unmet needs remain due to treatment-related toxicities, teratogenic risks, and the emergence of resistance, limiting long-term therapy use and underscoring the urgent need for safer, disease-specific therapies.

Emerging therapies are reshaping the research landscape, with agents like SGT-610 (Patidegib Gel 2%), a topical Hedgehog pathway inhibitor, aiming to minimize systemic exposure and associated toxicities while effectively reducing tumor burden. SUBA-Itraconazole, similarly represents a shift toward targeted, mechanism-based, and better-tolerated therapies that could expand treatment options beyond the current off-label systemic Hedgehog inhibitors. The off-label use of systemic Hedgehog pathway inhibitors has underscored a balance between efficacy and safety, prompting increased interest in topical treatments and next-generation SMO inhibitors. Due to its small, rare-disease population and the high cost of treatment, BCNS is well-suited for orphan drug exclusivity strategies and potential public-private partnerships aimed at promoting innovation and improving patient access. Over the next decade, the market is expected to witness steady growth driven by these novel agents, genetic screening programs, and precision medicine strategies, with the potential to transform Gorlin syndrome management if clinical trials demonstrate efficacy and safety.

Learn more about the emerging therapies for BCNS @ https://www.delveinsight.com/sample-request/basal-cell-nevus-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Scope of the Basal Cell Nevus Syndrome Market Report

Coverage- 7MM
Study Period- 2020-2034
Forecast Period- 2025-2034
BCNS Companies- Ono Pharmaceuticals, Bristol Myers Squibb, Jazz Pharmaceuticals, Sol-Gel Technologies, Inhibitor Therapeutics, and others.
BCNS Pipeline Therapies- SGT-610 (Patidegib Gel 2%), SUBA-Itraconazole, ONO-4538, ONC206, and others.
BCNS Therapeutic Assessment: BCNS current marketed and BCNS emerging therapies
BCNS Market Dynamics: BCNS market drivers and BCNS market barriers
BCNS Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
BCNS Unmet Needs, KOL’s views, Analyst’s views, BCNS Market Access and Reimbursement

Table of Content

Key Insights
Report Introduction
Basal Cell Nevus Syndrome Market Overview at a Glance
Epidemiology and Market Forecast Methodology of BCNS
Executive Summary of BCNS
Key Events
Disease Background and Overview
Epidemiology and Patient Population
Patient Journey
Marketed Drugs and Treatment Approaches
Emerging Drugs
BCNS: Seven Major Market Analysis
KOL Views
SWOT Analysis
Unmet Needs
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

Discover which therapies are expected to grab the Basal Cell Nevus Syndrome Market Share

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Basal Cell Nevus Syndrome (BCNS) Therapeutics Market Expected to Witness Significant Growth Through 2034, estimates DelveInsight